Triangle Capital Corporation Announces Commencement of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Triangle Capital Corporation Announces Commencement of Public Offering of Common Stock

RALEIGH, N.C., July 25, 2016 (GLOBE NEWSWIRE) -- Triangle Capital Corporation  (NYSE: TCAP ) (“Triangle” or the “Company”) today announced the commencement of an underwritten public offering of 6,250,000 shares of common stock. The Company also plans to grant the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock.

The Company intends to invest the net proceeds of this public offering in lower middle market companies in accordance with its investment objective and strategies, and for working capital and general corporate purposes.

Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, A Stifel Company , BofA Merrill Lynch, Wells Fargo Securities, LLC and Robert W. Baird & Co. Incorporated are acting as joint bookrunning managers of this offering. BB&T Capital Markets, a division of BB&T Securities, LLC, and Janney Montgomery Scott LLC are acting as lead managers, and JMP Securities LLC, Wunderlich Securities, Inc. and Houlihan Lokey Capital, Inc. are acting as co-managers for this offering.

This offering will be made pursuant to an effective shelf registration statement on Form N-2 that has been filed with the U.S. Securities and Exchange Commission. The offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained, when available, from any of the following investment banks: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Keefe, Bruyette & Woods, A Stifel Company , 787 Seventh Avenue, 4th Floor, New York, NY 10019 (telephone number: 1-800-966-1559); BofA Merrill Lynch, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina, 28255-0001, or by emailing dg.prospectus_requests@baml.com ; Wells Fargo Securities, LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152-4077 (telephone number: 1-800-326-5897), or by emailing cmclientsupport@wellsfargo.com or Robert W. Baird & Co. Incorporated, Attn: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, WI 53202 (telephone number: 1-800-792-2473), or by emailing syndicate@rwbaird.com . Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing. The prospectus supplement and prospectus contain this and other information about the Company and should be read carefully before investing.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the shares referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Triangle Capital Corporation

Triangle Capital Corporation ( www.TCAP.com ) invests capital in established companies in the lower middle market to fund growth, changes of control and other corporate events.  Triangle offers a wide variety of investment structures with a primary focus on mezzanine financing with equity components.  Triangle’s investment objective is to seek attractive returns by generating current income from debt investments and capital appreciation from equity related investments.  Triangle’s investment philosophy is to partner with business owners, management teams and financial sponsors to provide flexible financing solutions.  Triangle typically invests $5.0 million – $35.0 million per transaction in companies with annual revenues between $20.0 million and $200.0 million and EBITDA between $3.0 million and $35.0 million.

Triangle has elected to be treated as a business development company under the Investment Company Act of 1940 (“1940 Act”).  Triangle is required to comply with a series of regulatory requirements under the 1940 Act as well as applicable NYSE, federal and state laws and regulations.  Triangle has elected to be treated as a regulated investment company under the Internal Revenue Code of 1986.  Failure to comply with any of the laws and regulations that apply to Triangle could have a material adverse effect on Triangle and its stockholders.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Any such statements, other than statements of historical fact, are likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under the Company’s control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance.  Actual developments and results are highly likely to vary materially from these estimates and projections of the future, and some of these uncertainties are enumerated in Triangle’s filings with the Securities and Exchange Commission.  Certain factors that could cause actual results to differ materially from those contained in the forward-looking statements are included in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, each as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website at www.sec.gov , and stockholders may receive a hard copy of the completed audited financial statements free of charge upon request to the Company at 3700 Glenwood Avenue, Suite 530, Raleigh, NC 27612. Such forward-looking statements speak only as of the time when made, and the Company undertakes no obligation to update any such statement now or in the future.

Contacts Sheri Blair Colquitt Vice President, Investor Relations 919-719-4784 scolquitt@tcap.com Steven C. Lilly Chief Financial Officer 919-719-4789 slilly@tcap.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

M&A Source's 2026 Conference Tackles Deal-Making Drama

Updated Category News Views 130

High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...

Continue Reading
Endava Faces Class Action: Investors Eye Their Next Move

Updated Category News Views 0

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Continue Reading
Astellas and Audax Forge $1.34B Immuno-Oncology Deal

Updated Category News Views 36

Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...

Continue Reading
OneQode & AdaniConneX Forge AI Path in India

Updated Category News Views 17

A Major Step Forward in AI Infrastructure When two heavyweights clash, you better believe folks are paying attention. OneQode’s deal with AdaniConneX is like a shot across the bow in the AI infrastructure arena. They’re not just dipping a toe in India’s tech waters; they’re diving headfirst with 14 MW of data center muscle right there in Siruseri Sipcot, Chennai....

Continue Reading
Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

Updated Category News Views 48

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Continue Reading
Brightstar's Cash Pop Shakes Up Illinois Lottery Scene

Updated Category News Views 63

A New Twist in Illinois: Cash Pop's Arrival Here's something fresh off the press: the Illinois Lottery is now on the ride with Brightstar's Cash Pop. This patented game isn't just another number pick—it's an engaging draw-based game featuring hourly draws with price tags of $1, $2, $5, and $10. It's like clockwork, and trust me, it's more than just the usual spin....

Continue Reading
Etisalat Surges: Net Profit Soars 46% Amid Growth

Updated Category News Views 91

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Continue Reading
Amgen Declares Q4 Dividend Amidst Broad Horizons

Updated Category News Views 16

Amgen's Steady Dividend: A Testament to Stability Diving into the mess that is today's biotech market, Amgen (NASDAQ:AMGN) stands out like a beacon of stability with its recent dividend announcement. The Board's decision to dole out a $2.52 per share dividend for the fourth quarter of 2026 showcases confidence amidst both promising ventures and looming uncertainties....

Continue Reading
2026 World Laureates Forum Drives Science Forward

Updated Category News Views 78

A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...

Continue Reading
Mercado González Opens, Integrates Mexican Culture

Updated Category News Views 27

Dive into Mercado González's Cultural Opening Over in La Habra, Northgate González Market has just flung open the doors to its latest masterpiece: Mercado González. Picture this, a place where the mundanity of grocery shopping melds with a vibrant fiesta of Mexican cuisine, artisanry, and cultural vibes. They transformed an older store into something that commands not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Exelon's Earnings: Insights and Future Potential

Updated Category News Views 142

Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...

Continue Reading
Vallourec Invites Warrant Holders to General Meeting

Updated Category News Views 157

Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...

Continue Reading
Investigation Initiated for Molina Healthcare Investors Following Financial Reports

Updated Category News Views 246

Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...

Continue Reading
How SymphonyAI's Insights Drive E-commerce Growth in Grocery

Updated Category News Views 159

Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...

Continue Reading
Exploring the Impact of Honda and Nissan's Potential Merger

Updated Category News Views 408

Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....

Continue Reading